Lv1
40 积分 2026-06-08 加入
The Trispecific Antibody IBI3019 Integrates CDH17-Enhanced EGFR Antagonism with Optimized CD16A Engagement to Elicit Potent Antitumor Activity with Minimal Toxicity
2天前
已完结
Trispecific antibodies in cancer therapy: Mechanisms, clinical progress and future directions
11天前
已完结
Recent advances in bispecific natural killer cell engagers for cancer immunotherapy
3个月前
已完结
Understanding the Therapeutic Potential of PD-1 Agonism in Inflammatory and Autoimmune Disorders
4个月前
已完结